证券代码：000566 证券简称：海南海药 公告编号：2024-030 海南海药股份有限公司关于参加 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "2023 年度海南辖区上市公司业绩说明会暨投资者集体接待日"活动，活动时 间为 2024 年 5 月 14 日 14:00-17:00，平台登陆地址为：http://rs.p5w.net。 届时，海南海药股份有限公司（以下简称"公司"）主要高管人员将参加本 次活动，通过网络在线交流形式，就公司 2023 年年报披露、财务数据、公司治 理、内部控制、发展战略、经营状况、现金分红、重大事项、可持续发展等投资 者所关心的问题，与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者 踊跃参与。 特此公告 海南海药股份有限公司 董 事 会 二〇二四年五月七日 1 "2023年度海南辖区上市公司业绩说明会暨投资者集体接待日" 的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,478,580,692.25, a decrease of 16.89% compared to CNY 1,779,052,190 in 2022[23]. - The net profit attributable to shareholders of the listed company was CNY 106,488,625.09, showing a significant decline from the previous year's figures[23]. - The company's operating revenue for 2023 was CNY 1,478,580,692.25, a decrease of 16.83% compared to CNY 1,779,052,193.18 in 2022[25]. - The net profit attributable to shareholders of the listed company was CNY -410,186,284, a decline of 66.32% from the previous year[24]. - The net cash flow from operating activities was CNY 103,548,849, down 27.17% from CNY 142,170,662 in 2022[24]. - The basic earnings per share for 2023 was CNY -0.0821, compared to CNY 0.0081 in 2022[24]. - Total assets at the end of 2023 were CNY 7,366,534,910, a slight decrease of 0.01% from CNY 7,365,442,820 at the end of 2022[24]. - The net assets attributable to shareholders of the listed company decreased by 4.73% to CNY 2,062,448,250 from CNY 2,164,791,380 in 2022[24]. - The company's total revenue for the reporting period was approximately ¥1.48 billion, a decrease of 16.89% compared to ¥1.78 billion in the previous year[59]. - The cost of sales decreased by 10.13% to approximately ¥908 million from ¥1.01 billion year-on-year[59]. - Research and development expenses amounted to approximately ¥130.79 million, down 8.07% from ¥142.28 million in the previous year[59]. - The revenue from the pharmaceutical segment was approximately ¥1.28 billion, accounting for 86.73% of total revenue, with a year-on-year decrease of 13.49%[61]. - The revenue from medical services increased by 1.66% to approximately ¥172.76 million, representing 11.68% of total revenue[61]. Operational Changes and Strategies - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves[6]. - The report indicates that the company is facing potential operational risks and has outlined corresponding countermeasures in the future development outlook section[5]. - The company has undergone accounting policy changes that necessitated restating previous financial data[23]. - The company has not made any changes to its main business since its establishment[21]. - The company plans to focus on innovation and research and development in response to the pressures from national policies affecting the pharmaceutical industry[35]. - The company achieved a significant breakthrough in R&D, establishing new research institutes and enhancing management capabilities, leading to a more focused and efficient R&D process[39]. - The company has successfully registered 11 drug varieties that have passed or are deemed to have passed consistency evaluations by the end of 2023[40]. - The company has established partnerships with renowned universities and research institutions to enhance its drug development capabilities[39]. - The company has implemented a series of policies to encourage drug innovation, optimizing the review process for new drug applications[37]. - The company is currently conducting clinical trials for Fibroblast Growth Factor and other innovative drugs, indicating a strong pipeline for future growth[54]. - The company plans to increase R&D investment to activate dormant approvals and develop new products, aiming to enhance its market position[57]. Market and Product Development - The company focuses on developing a full industry chain model centered on anti-infection drugs, with a strategic emphasis on various therapeutic areas including anti-infection, neuropsychiatric, digestive, cardiovascular, and oncology[53]. - The company has established R&D centers in multiple locations including Haikou and Chongqing to enhance collaboration between industry and academia, fostering a diverse technological innovation model[53]. - The company has a comprehensive procurement management system that utilizes sales forecasts, production plans, and safety stock levels to optimize purchasing processes and reduce costs[51]. - The sales model has been adjusted to include eight promotional strategies, enhancing the effectiveness of sales channels and improving market penetration[51]. - The company exports raw materials and intermediates to over 30 countries across three continents, establishing a solid international sales network[52]. - The company has developed a range of antibiotics, including various injectable formulations targeting sensitive bacteria responsible for respiratory and urinary tract infections[47]. - The company’s gastrointestinal medication series addresses acute gastroenteritis and constipation symptoms, showcasing its diverse product offerings[49]. - The company is actively involved in the production of active pharmaceutical ingredients (APIs) and intermediates, contributing to its overall revenue stream[49]. - The company has launched several new products, including Cefoperazone Sodium Injection and Dexamethasone Sodium Phosphate Injection, which have passed consistency evaluations in 2023[54]. - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the market[129]. Financial Management and Governance - The company has taken measures to ensure the accuracy of its financial reporting[98]. - The company has revised its governance structure to comply with legal regulations, ensuring effective decision-making and accountability[113]. - The company maintains independence from its controlling shareholder in terms of operations, finance, and management, ensuring a clear separation of interests[117]. - The company has established independent financial management systems, including a dedicated finance department and independent bank accounts[120]. - The company reported a total of 425.3 million shares held by its executives and board members at the end of the reporting period, with no changes in holdings during the period[122]. - The company has a total of 72 independent directors and supervisors, indicating a strong governance structure[123]. - The company is committed to ongoing research and development to enhance its product offerings and market competitiveness[150]. - The company has implemented a differentiated incentive mechanism for senior management, linking compensation to operational performance and budget completion[156]. - The company emphasizes the protection of minority shareholders' rights in its profit distribution policy[159]. - The internal control system has been established with no significant defects in financial reporting, ensuring compliance and effectiveness[163]. Environmental and Social Responsibility - Hainan Haiyao Co., Ltd. strictly adheres to environmental protection policies, ensuring wastewater and waste gas emissions meet regulatory standards[169]. - The company has a valid pollutant discharge permit effective until August 31, 2027, applied on September 1, 2022[173]. - The company has implemented a comprehensive waste management strategy in compliance with national regulations, including hazardous waste storage and disposal[172]. - The company has successfully passed environmental inspections for several projects, demonstrating compliance with environmental standards[174]. - Hainan Haiyao has invested significantly in environmental protection, ensuring that all pollutants are discharged in accordance with standards, with no exceedances reported since 2016[182]. - The company has developed a comprehensive plan for pollution prevention and control, aligning with national and local environmental regulations[185]. - The companies implemented various energy-saving and carbon reduction measures, as detailed in their 2023 ESG reports[189]. - The commitment to avoid competition and ensure independence in operations was reiterated by the controlling shareholder of Hainan Haiyao Co., Ltd.[192]. Future Outlook and Strategic Goals - The company plans to implement a "Capability Enhancement Year" in 2024 to optimize business structure and improve operational quality across key areas[104]. - Hainan Haiyao's 2024 strategy includes strengthening technological innovation and enhancing market development to achieve annual revenue targets[105]. - The company will focus on expanding into second, third, and fourth-tier markets, particularly targeting chain pharmacies and e-commerce[106]. - The company has set ambitious performance guidance for the next fiscal year, targeting a revenue increase of 15%[128]. - The management team emphasized the importance of sustainability in future operations, aiming for a 20% reduction in carbon footprint by 2025[139]. - The company is actively pursuing market expansion, targeting three new provinces for service delivery by the end of the year[141].

Financial Performance - The company's revenue for Q1 2024 was ¥363,023,438.22, a decrease of 26.67% compared to ¥495,029,847.71 in the same period last year[5] - The net loss attributable to shareholders was ¥15,842,321.07, compared to a profit of ¥4,669,720.32 in the previous year[5] - The basic earnings per share for the period was -¥0.0122, compared to ¥0.0036 in the same period last year[5] - The net profit for the first quarter of 2024 was -24,451,294.07 CNY, compared to a profit of 523,222.02 CNY in the same period last year, indicating a significant decline[27] - The company reported a total comprehensive income of -24,423,790.61 CNY for the quarter, compared to -685,170.80 CNY in the previous year, indicating a worsening financial position[28] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 1,253.35% to ¥21,998,961.19 from ¥1,625,521.45 year-on-year[5] - The cash and cash equivalents net increase was ¥867,620.57, a significant decrease of 99.56% compared to the previous year[8] - The cash and cash equivalents at the end of the period were 304,717,701.02 CNY, down from 521,518,921.53 CNY year-over-year, representing a decrease of approximately 41.5%[29] - The company incurred a total investment cash outflow of 58,920,960.34 CNY, compared to 69,837,238.32 CNY in the previous year, showing a reduction in investment activities[29] - The financing cash inflow for the quarter was 946,572,741.84 CNY, a decrease from 1,370,314,080.63 CNY year-over-year, indicating a decline in financing activities[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,475,447,154.87, an increase of 1.48% from the previous year[5] - The total liabilities increased to ¥5,299,507,428.24 from ¥5,166,171,398.76, indicating a rise of 2.58%[25] - Short-term borrowings decreased significantly to ¥1,404,019,398.85 from ¥1,787,108,904.77, a reduction of 21.43%[24] - The company's total equity attributable to shareholders decreased by 0.77% to ¥2,046,633,439.11 from ¥2,062,448,256.73 at the end of the previous year[5] Research and Development - Research and development expenses rose by 49.48% to ¥22,999,618.72, reflecting increased investment in R&D projects[8] - Research and development expenses increased to ¥22,999,618.72, representing a 49.4% increase from ¥15,386,422.96 in the previous period[26] Debt and Financial Assistance - The company provided financial assistance of up to RMB 300 million to Chongqing Sino Biological Co., Ltd. for the repayment of debts[12] - As of December 25, 2023, Sino Biological has repaid RMB 200 million of the total debt of RMB 320 million, with RMB 120 million due by December 31, 2023, and the remaining amount by December 31, 2024[12] - The company signed a debt confirmation and transfer agreement with Chongqing Jin Sai, requiring repayment of RMB 144.5 million by December 31, 2022, with an interest rate of 4.35%[13] - As of December 31, 2023, the remaining target debt from Chongqing Sino and Chongqing Jin Sai is RMB 277.79 million[14] - The company has completed the transfer of two drug approvals and their intellectual property from Sino Biological to offset debts owed by Chongqing Jin Sai, valued at RMB 53.3342 million[13] - The company signed a debt repayment agreement with Hainan Haiyao and other parties, with the assessed value of the asset group for repayment set at RMB 281.40 million[15] - The company transferred receivables worth RMB 446.36 million to Nanfang Tongzheng, with 35% of the future sales revenue from a real estate project allocated for debt repayment[15] - The company is owed RMB 150 million by Nanfang Tongzheng and Hainan Haiyao Real Estate, with RMB 18 million received in 2021 and RMB 1.08 million in 2022, leaving outstanding debts of RMB 132 million and RMB 179.2 million respectively[16] - The company agreed to accept 101 residential units valued at RMB 132 million as repayment for debts owed by Nanfang Tongzheng and Hainan Haiyao Real Estate[17] - A supplementary agreement was signed to accept 110 residential units valued at RMB 179.2 million for the remaining debt from 2022, with cash compensation for any shortfall[18] - The company initiated legal proceedings against Nanfang Tongzheng and Hainan Haiyao Real Estate for failure to comply with the agreement regarding the residential units[19] Regulatory Compliance - The company received a warning and a fine of RMB 2 million from the China Securities Regulatory Commission for violations related to information disclosure[21]

证券代码：000566 证券简称：海南海药 公告编号：2024-018 海南海药股份有限公司 关于收到《行政处罚决定书》的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"海南海药"或"公司"）及公司原实际 控制人刘悉承先生于 2023 年 9 月 28 日收到中国证券监督管理委员会（以下简 称"中国证监会"）的《立案告知书》（证监立案字 2023029007 号）、（证监 立案字 2023029008 号），因涉嫌信息披露违法违规，根据《中华人民共和国证 券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司及原 实际控制人、公司副董事长刘悉承先生立案。公司于 2024 年 4 月 12 日收到中国 证券监督管理委员会海南监管局《行政处罚事先告知书》（【2024】1 号）。具 体内容详见公司于 2023 年 9 月 29 日及 2024 年 4 月 13 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于公司及原实际控制人收到中国证券监督管 理委员会立案告知书的公告》及《关于收到<行政处罚事先告知 ...

公司部关注函〔2024〕第 61 号 2018 年 12 月至 2020 年 1 月，海南海药及其子公司以财务 资助、购买信托理财等名义，通过直接间接划款的方式，与重庆 赛诺、重庆金赛发生非经营性资金占用的关联交易。2018 年至 2020 年非经营性资金占用发生额分别为 48,000 万元、22,000 万 1 关于对海南海药股份有限公司的关注函 海南海药股份有限公司董事会： 中国证券监督管理委员会海南监管局《行政处罚事先告知书》 （〔2024〕1 号）显示，海南海药股份有限公司（以下简称海南 海药或公司）及相关当事人存在以下违规行为： 深 圳 证 券 交 易 所 一、关联方情况 刘悉承是海南海药原实际控制人，时任董事长、副董事长、 总经理，能够对重庆赛诺生物药业股份有限公司（以下简称重庆 赛诺）、重庆金赛医药有限公司（以下简称重庆金赛）施加重大 影响，重庆赛诺、重庆金赛为海南海药的关联方。 二、未在定期报告中披露关联交易 特此函告。 深圳证券交易所 上市公司管理二部 2024 年 4 月 12 日 2 元、4,750 万元。海南海药未按规定在 2018 年年度报告、2019 年年度报告、2020 年年度报 ...

证券代码：000566 证券简称：海南海药 公告编号：2024-014 审议通过《关于签订租赁合同暨关联交易的议案》 公司全资子公司海口市制药厂有限公司将部分资产租赁给公司关联方中抗 生物制药（海口）有限公司，年租金 536.43 万元，租赁期限自 2024 年 4 月 1 日 至 2027 年 3 月 31 日，共计 3 年，租金合计为 1,609.29 万元。 根据《深圳证券交易所股票上市规则》相关规定，本次交易构成关联交易， 不构成《上市公司重大资产重组管理办法》规定的重大资产重组。在董事会审议 之前，该议案已经公司董事会独立董事专门会议审议通过，全体独立董事同意将 该 议 案 提 交 董 事 会 审 议 。 具 体 内 容 详 见 同 日 刊 载 于 巨 潮 资 讯 网 （http//www.cninfo.com.cn）的《关于签订租赁合同暨关联交易的公告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 特此公告 海南海药股份有限公司 第十一届董事会第九次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简 ...

证券代码：000566 证券简称：海南海药 公告编号：2024-015 海南海药股份有限公司 1 关于签订租赁合同暨关联交易的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、概述 （一）关联交易基本情况 因海南海药股份有限公司（以下简称"公司"或"海南海药"）全资子公司 海口市制药厂有限公司（以下简称"海口市制药厂"）拟将部分资产租赁给公司 关联方中抗生物制药（海口）有限公司（以下简称"中抗生物"），双方签署了海 药 6#抗体楼租赁协议，租赁期限自 2024 年 4 月 1 日至 2027 年 3 月 31 日，共计 3 年，租金合计为 1609.29 万元。 （二）关联关系介绍 中抗生物为深圳赛乐敏生物科技有限公司（以下简称"深圳赛乐敏"）全资 子公司，深圳赛乐敏为中国抗体制药有限公司（以下简称"中国抗体"）全资子 公司，中国抗体为海南海药参股公司，公司因管理需要向中国抗体委派了董事， 公司副总经理、董事会秘书石磊先生担任中国抗体董事职务。根据《深圳证券交 易所股票上市规则》，本次交易构成关联交易。 （三）关联交易履行的审议程序 公司于 2024 年 ...

证券代码：000566 证券简称：海南海药 公告编号：2024-016 海南海药股份有限公司 关于收到《行政处罚事先告知书》的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）及公司原实际控制人刘悉承先 生于 2023 年 9 月 28 日收到中国证券监督管理委员会（以下简称"中国证监 会"）的《立案告知书》（证监立案字 2023029007 号）、（证监立案字 2023029008 号），因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共 和国行政处罚法》等法律法规，中国证监会决定对公司及原实际控制人、公司副 董事长刘悉承先生立案。具体内容详见公司于 2023 年 9 月 29 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于公司及原实际控制人收到中国证券监督管理委 员会立案告知书的公告》。 公司于 2024 年 4 月 12 日收到中国证券监督管理委员会海南监管局《行政处 罚事先告知书》（【2024】1 号），现将相关内容公告如下： 一、《行政处罚事先告知书》的主要内容 海南海药股份 ...

海南海药股份有限公司 章程 二〇二四年四月 1 （经 2024 年 4 月 2 日公司 2024 年第一次临时股东大会审议通过） 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称 《证券法》）、《中国共产党章程》和其他有关规定，制订本章程。 第二条 公司系依照《股票发行与交易管理暂行条例》和国家体改委《股份有限公 司规范意见》、《海南经济特区股份有限公司条例》等有关规定成立的股份有限公司（以 下简称"公司"）。 公司经海南省股份制试点领导小组办公室（琼股办字[1992]10 号文）批准，以定向 募集方式设立；在海南省市场监督管理局注册登记，取得营业执照。统一社会信用代码： 91460000201289453D。 《公司法》实施后，公司已按照有关规定对照《公司法》进行了规范并依法履行了重 新登记手续。 第三条 公司于 1993 年 12 月 29 日经中国证券监督管理委员会（证监发字[1993]115 号文）批准，首次向社会公众发行人民币普通股 A 股 2500 万股，于 1994 年 5 月 ...

北京中伦（海口）律师事务所 关于海南海药股份有限公司 本所律师根据《股东大会规则》第五条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责的精神，对本次股东大会所涉及的有关事项和相关文件 进行了必要的核查和验证，出席了本次股东大会，出具法律意见如下： 1 一、本次股东大会的召集、召开程序 （一）本次股东大会的召集程序 本次股东大会由公司董事会提议并召集。2024年3月15日，公司召开第十一 届董事会第八次会议，审议通过了《关于召开2024年第一次临时股东大会的议案》， 同意于2024年4月2日召开公司2024年第一次临时股东大会。 公司于2024年3月16日在深圳证券交易所官方网站、巨潮资讯网及《中国证 券报》等媒体公告了《关于召开2024年第一次临时股东大会的通知》（以下简称 "《股东大会通知》"），详细说明了本次股东大会的召开时间和地点、会议审议事 项、出席会议人员资格、会议登记事项等相关事项。本次股东大会股权登记日为 2024年3月26日。 2024 年第一次临时股东大会的法律意见书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下 ...